Inicio › Leucemia linfocítica crónica › Ohio › Columbus
Ensayos clínicos de Leucemia linfocítica crónica en Columbus, OH
29 estudios para Leucemia linfocítica crónica buscan participantes en centros de Columbus y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ReclutandoFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
ReclutandoFase 3
- OSU Comprehensive Cancer Center, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
HPC Offered for PRESERVE Expansion
ReclutandoEstudio observacional
- The Ohio State University Medical Center, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
ReclutandoFase 1
- The James Cancer Hospital and Solove Research Institute, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- y 8 más
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ReclutandoFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- y 8 más
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ReclutandoFase 2
- The Ohio State University, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
ReclutandoFase 1/2
- Research Site, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutandoFase 1/2
- The Ohio State University Wexner Medical Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
ReclutandoFase 2
- The Ohio State University Comprehensive Cancer Center, Columbus
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
ReclutandoFase 3
- Study Site 104, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
ReclutandoFase 1
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
ReclutandoFase 1
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutandoFase 1
- The Ohio State University, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
ReclutandoFase 2
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
ReclutandoFase 1
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
ReclutandoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Ensayos de Leucemia linfocítica crónica en otras ciudades
- Boston, MA31 estudios
- Durham, NC28 estudios
- Washington, DC22 estudios
- Seattle, WA22 estudios
- Rochester, MN20 estudios
- New York City, NY20 estudios
- Houston, TX18 estudios
- Baldwin Park, CA18 estudios
- Cincinnati, OH15 estudios
- Milwaukee, WI15 estudios
- Chicago, IL14 estudios
- Nashville, TN13 estudios
Otros estudios en Columbus
- Cáncer de pulmón de células no pequeñas57 estudios
- Cáncer (todos los tipos)40 estudios
- Cáncer de seno39 estudios
- Cáncer de ovario39 estudios
- Cáncer de pulmón36 estudios
- Leucemia mielógena aguda34 estudios
- Cáncer metastásico25 estudios
- Mieloma múltiple25 estudios
- Cáncer de próstata25 estudios
- Cáncer de endometrio24 estudios
- Cáncer del colon y del recto24 estudios
- Melanoma21 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.